Pericardial Mesothelioma Prognosis

Pericardial Mesothelioma Prognosis can vary from 10 months to 5 years. In most cases, the delay in onset of pericardial mesothelioma symptoms allows the disease to go undiagnosed for a long period of time, allowing it to progress to a very advanced stage. By that point, though, the disease has progressed to a detrimental point. Given the difficulties associated with diagnosing the condition until the tumors are advanced, the prognosis is sometimes dismal.

What Affects a Pericardial Mesothelioma Prognosis?

Factors influencing prognosis include tumor size, tumor location, potential for surgical removal of those tumors, presence of fluid around the heart, patient age, other health problems, and history of cigarette smoking.

Cell type is important, too, as it determines what kind of treatment options will work best and thereby affects the prognosis. The first of the three cellular varieties of mesothelioma is epithelioid, which accounts for 60 to 70 percent of cases, and it has the most favorable prognosis. The much more aggressive sarcomatoid subtype comprises 10 to 15 percent of cases. The biphasic subtype exists in another 10 to 25 percent of cases, and it exhibits features of both of the other subtypes. The mixed subtype has the lowest survival rate.

Treatment Options

For a few patients, aggressive treatment using radiation, chemotherapy, and/or surgery may yield a hope of survival. Staging, or classifying the tumor based on size and degree of spread, aids doctors in choosing appropriate therapies. Chest x-rays, CT scans, MRIs, and PET scans establish the stage.

A tumor is considered to be in Stage I if it can be surgically removed with no lymph node involvement. Stage II refers to a tumor than can be removed, but tumor cells have spread to the lymph nodes. Once the tumor can no longer be extracted and it has spread to other organs, the tumor is at Stage III. Stage IV is reached when the tumor has completely metastasized throughout the body. Patients in Stage III and Stage IV have few treatment options. Therefore, they are considered terminal.

Overall, the survival rate for mesothelioma patients is about five years. The likelihood of surviving one year after diagnosis is currently at 40 percent. The average length of survival after diagnosis is approximately 10 to 11 months. For pericardial mesothelioma, the average survival duration after diagnosis drops to six months. Some patients outlive this expectation by taking advantage of alternative treatment options or taking part in clinical trials. Given that, there is hope upon Pericardial Mesothelioma Prognosis.